f | { | f | { |
| "author": "", | | "author": "", |
| "author_email": "", | | "author_email": "", |
| "creator_user_id": "0124c449-4279-4839-a7e2-f7ee873dbc7c", | | "creator_user_id": "0124c449-4279-4839-a7e2-f7ee873dbc7c", |
| "groups": [ | | "groups": [ |
| { | | { |
| "description": "Group for publications", | | "description": "Group for publications", |
| "display_name": "Publication", | | "display_name": "Publication", |
| "id": "816c3c41-f871-427d-9e26-fb21e6b3c578", | | "id": "816c3c41-f871-427d-9e26-fb21e6b3c578", |
| "image_display_url": | | "image_display_url": |
| mw/uploads/group/2022-03-17-123757.433896243660articlesquareicon.png", | | mw/uploads/group/2022-03-17-123757.433896243660articlesquareicon.png", |
| "name": "publication", | | "name": "publication", |
| "title": "Publication" | | "title": "Publication" |
| } | | } |
| ], | | ], |
| "id": "e493a8c3-5775-45ab-9189-016bfccfdb96", | | "id": "e493a8c3-5775-45ab-9189-016bfccfdb96", |
| "isopen": false, | | "isopen": false, |
| "license_id": "notspecified", | | "license_id": "notspecified", |
| "license_title": "License not specified", | | "license_title": "License not specified", |
| "maintainer": null, | | "maintainer": null, |
| "maintainer_email": null, | | "maintainer_email": null, |
| "metadata_created": "2021-10-14T11:03:14.464072", | | "metadata_created": "2021-10-14T11:03:14.464072", |
n | "metadata_modified": "2022-04-27T11:35:13.180708", | n | "metadata_modified": "2022-04-27T11:36:00.508203", |
| "name": "malawi-tb-program-report-2014", | | "name": "malawi-tb-program-report-2014", |
| "notes": "This is the 14th quarterly HIV Program report after | | "notes": "This is the 14th quarterly HIV Program report after |
| implementation of the 2011 Integrated Clinical HIV Guidelines in July | | implementation of the 2011 Integrated Clinical HIV Guidelines in July |
| 2011. A summary of the key achievements between October and December | | 2011. A summary of the key achievements between October and December |
| 2014 is provided below:\r\n\r\n* Scale-up of integrated HIV services | | 2014 is provided below:\r\n\r\n* Scale-up of integrated HIV services |
| had reached the following number of sites:\r\n\r\n * __724__ static | | had reached the following number of sites:\r\n\r\n * __724__ static |
| (579 within and 145 outside of health facilities) and 188 outreach HTC | | (579 within and 145 outside of health facilities) and 188 outreach HTC |
| sites\r\n\r\n * __713__ (static) ART sites\r\n\r\n * __615__ | | sites\r\n\r\n * __713__ (static) ART sites\r\n\r\n * __615__ |
t | PMTCT sites (Option B+, all included in ART sites above)\r\n\r\n | t | PMTCT sites (Option B+, all included in ART sites above)\r\n\r\n * |
| *__655__ Pre-ART sites\r\n\r\n *__644__ sites with HIV-exposed | | __655__ Pre-ART sites\r\n\r\n * __644__ sites with HIV-exposed |
| child follow-up\r\n\r\n* 464,292 persons were tested and counselled | | child follow-up\r\n\r\n* 464,292 persons were tested and counselled |
| for HIV; __139,602 (30%)__ accessed HTC for the first time; __324,690 | | for HIV; __139,602 (30%)__ accessed HTC for the first time; __324,690 |
| (70%)__ were repeat testers and __9,854 (3%)__ of these received | | (70%)__ were repeat testers and __9,854 (3%)__ of these received |
| confirmatory testing (after having tested positive in the past). This | | confirmatory testing (after having tested positive in the past). This |
| is equivalent to 38% confirmatory testing coverage among __26,060__ | | is equivalent to 38% confirmatory testing coverage among __26,060__ |
| patients initiating ART this quarter. __28,465 (6%)__ clients received | | patients initiating ART this quarter. __28,465 (6%)__ clients received |
| a positive result for the first time.\r\n\r\n* __19,606 (97%)__ of | | a positive result for the first time.\r\n\r\n* __19,606 (97%)__ of |
| __20,244__ blood units collected were screened for (at least) HIV, | | __20,244__ blood units collected were screened for (at least) HIV, |
| hepatitis B and syphilis.\r\n\r\n* __134,985 (89%)__ of __151,118__ | | hepatitis B and syphilis.\r\n\r\n* __134,985 (89%)__ of __151,118__ |
| women at ANC had their HIV status ascertained; __10,550 (8%)__ of | | women at ANC had their HIV status ascertained; __10,550 (8%)__ of |
| these were HIV positive. __129,821 (96%)__ of __138,024__ women at | | these were HIV positive. __129,821 (96%)__ of __138,024__ women at |
| maternity had their HIV status ascertained __9,785 (8%)__ of these | | maternity had their HIV status ascertained __9,785 (8%)__ of these |
| were HIV positive.\r\n\r\n* __26,060__ patients started ART this | | were HIV positive.\r\n\r\n* __26,060__ patients started ART this |
| quarter.\r\n\r\n* __536,438__ patients were alive and on ART by end of | | quarter.\r\n\r\n* __536,438__ patients were alive and on ART by end of |
| December 2014. This means that 54% of the estimated 1 million HIV | | December 2014. This means that 54% of the estimated 1 million HIV |
| positive population was on ART. 1 Estimated ART coverage among people | | positive population was on ART. 1 Estimated ART coverage among people |
| in need for treatment was __42% (46,410 / 111,000)__ for children (<15 | | in need for treatment was __42% (46,410 / 111,000)__ for children (<15 |
| years) and 71% (489,775 / 687,000) for adults.\r\n\r\n* __76%__ of | | years) and 71% (489,775 / 687,000) for adults.\r\n\r\n* __76%__ of |
| adults and __77%__ of children were retained alive on ART at 12 months | | adults and __77%__ of children were retained alive on ART at 12 months |
| after initiation. Actual retention rates are thought to be about 10% | | after initiation. Actual retention rates are thought to be about 10% |
| higher due to misclassification of \u2018silent transfers\u2019 as | | higher due to misclassification of \u2018silent transfers\u2019 as |
| defaulters in clinic-based survival/retention analysis. (see section | | defaulters in clinic-based survival/retention analysis. (see section |
| 16.4)\r\n\r\n* __470,048 (93%)__ of __504,494__ patients on first line | | 16.4)\r\n\r\n* __470,048 (93%)__ of __504,494__ patients on first line |
| adult ART were on regimen 5A (TDF/3TC/EFV).\r\n\r\n* __11,053 2 | | adult ART were on regimen 5A (TDF/3TC/EFV).\r\n\r\n* __11,053 2 |
| (85%)__ of an estimated __13,317__ HIV infected pregnant women in | | (85%)__ of an estimated __13,317__ HIV infected pregnant women in |
| Malawi were on ART this quarter. __6,288 (57%)__ of these were already | | Malawi were on ART this quarter. __6,288 (57%)__ of these were already |
| on ART when getting pregnant and 4,765 (43%) started ART during | | on ART when getting pregnant and 4,765 (43%) started ART during |
| pregnancy/delivery.\r\n\r\n* An additional __1,593__ breastfeeding | | pregnancy/delivery.\r\n\r\n* An additional __1,593__ breastfeeding |
| women started ART due to Option B+ (in WHO stage 1/2)\r\n\r\n* | | women started ART due to Option B+ (in WHO stage 1/2)\r\n\r\n* |
| __78%__, __72%__, __68%__ and __71%__ of women started under Option B+ | | __78%__, __72%__, __68%__ and __71%__ of women started under Option B+ |
| were retained on ART at 6, 12, 24 and 36 months after initiation, | | were retained on ART at 6, 12, 24 and 36 months after initiation, |
| respectively.\r\n\r\n* __8,851 (7%)__ of infants discharged alive from | | respectively.\r\n\r\n* __8,851 (7%)__ of infants discharged alive from |
| maternity were known to be HIV exposed, __8,305 (94%)__ of these | | maternity were known to be HIV exposed, __8,305 (94%)__ of these |
| received ARV prophylaxis (nevirapine). __7,006 (65%)__ were enrolled | | received ARV prophylaxis (nevirapine). __7,006 (65%)__ were enrolled |
| in exposed child follow-up before age 2 months.\r\n\r\n* A total of | | in exposed child follow-up before age 2 months.\r\n\r\n* A total of |
| __10,797__ HIV exposed children and __6,483__ pre-ART patients were | | __10,797__ HIV exposed children and __6,483__ pre-ART patients were |
| enrolled for follow-up in HIV Care Clinics (HCC) during this | | enrolled for follow-up in HIV Care Clinics (HCC) during this |
| quarter.", | | quarter.", |
| "num_resources": 1, | | "num_resources": 1, |
| "num_tags": 1, | | "num_tags": 1, |
| "organization": { | | "organization": { |
| "approval_status": "approved", | | "approval_status": "approved", |
| "created": "2021-10-14T11:02:35.234558", | | "created": "2021-10-14T11:02:35.234558", |
| "description": "The Department of HIV & AIDS (DHA) was established | | "description": "The Department of HIV & AIDS (DHA) was established |
| in 2001, initially as a unit in the Department of Clinical Services, | | in 2001, initially as a unit in the Department of Clinical Services, |
| to coordinate the biomedical HIV Program in Malawi. The department now | | to coordinate the biomedical HIV Program in Malawi. The department now |
| carries responsibility for various HIV related programs including: | | carries responsibility for various HIV related programs including: |
| sexually transmitted infections (STIs), prevention of mother to child | | sexually transmitted infections (STIs), prevention of mother to child |
| transmission of HIV (PMTCT), and national voluntary male medical | | transmission of HIV (PMTCT), and national voluntary male medical |
| circumcision program (VMMC). All these HIV program sub-sections are | | circumcision program (VMMC). All these HIV program sub-sections are |
| linked to one robust monitoring and evaluation sub-section in the HIV | | linked to one robust monitoring and evaluation sub-section in the HIV |
| and AIDS Department which technically operates under the Central | | and AIDS Department which technically operates under the Central |
| Monitoring and Evaluation Department (CMED) of the Ministry of | | Monitoring and Evaluation Department (CMED) of the Ministry of |
| Health.", | | Health.", |
| "id": "ca6a5fbb-31b1-44f8-9319-5da56d75a55b", | | "id": "ca6a5fbb-31b1-44f8-9319-5da56d75a55b", |
| "image_url": | | "image_url": |
| 2022-04-18-074318.527302WhatsApp-Image-2022-04-18-at-9.42.07-AM.jpeg", | | 2022-04-18-074318.527302WhatsApp-Image-2022-04-18-at-9.42.07-AM.jpeg", |
| "is_organization": true, | | "is_organization": true, |
| "name": "dha", | | "name": "dha", |
| "state": "active", | | "state": "active", |
| "title": "Department of HIV & AIDS and Viral Hepatitis", | | "title": "Department of HIV & AIDS and Viral Hepatitis", |
| "type": "organization" | | "type": "organization" |
| }, | | }, |
| "owner_org": "ca6a5fbb-31b1-44f8-9319-5da56d75a55b", | | "owner_org": "ca6a5fbb-31b1-44f8-9319-5da56d75a55b", |
| "private": false, | | "private": false, |
| "program_area": "Care and Treatment", | | "program_area": "Care and Treatment", |
| "relationships_as_object": [], | | "relationships_as_object": [], |
| "relationships_as_subject": [], | | "relationships_as_subject": [], |
| "resources": [ | | "resources": [ |
| { | | { |
| "cache_last_updated": null, | | "cache_last_updated": null, |
| "cache_url": null, | | "cache_url": null, |
| "created": "2022-03-23T19:56:25.534978", | | "created": "2022-03-23T19:56:25.534978", |
| "description": "", | | "description": "", |
| "format": "PDF", | | "format": "PDF", |
| "hash": "", | | "hash": "", |
| "id": "4fa63f06-2ae6-4a2c-9745-68363c56418a", | | "id": "4fa63f06-2ae6-4a2c-9745-68363c56418a", |
| "last_modified": "2022-04-27T11:12:28.548269", | | "last_modified": "2022-04-27T11:12:28.548269", |
| "lfs_prefix": "dha/malawi-tb-program-report-2014", | | "lfs_prefix": "dha/malawi-tb-program-report-2014", |
| "metadata_modified": "2022-04-27T11:12:28.559652", | | "metadata_modified": "2022-04-27T11:12:28.559652", |
| "mimetype": "application/pdf", | | "mimetype": "application/pdf", |
| "mimetype_inner": null, | | "mimetype_inner": null, |
| "name": "malawi-tb-program-report-2014", | | "name": "malawi-tb-program-report-2014", |
| "package_id": "e493a8c3-5775-45ab-9189-016bfccfdb96", | | "package_id": "e493a8c3-5775-45ab-9189-016bfccfdb96", |
| "position": 0, | | "position": 0, |
| "resource_type": null, | | "resource_type": null, |
| "sha256": | | "sha256": |
| "646d7add4ff1a31a4aa5a2e2f484bfa6ed55879f15ead55f428236cadcedf49e", | | "646d7add4ff1a31a4aa5a2e2f484bfa6ed55879f15ead55f428236cadcedf49e", |
| "size": 2005771, | | "size": 2005771, |
| "state": "active", | | "state": "active", |
| "url": | | "url": |
| e6-4a2c-9745-68363c56418a/download/malawi-tb-program-report-2014.pdf", | | e6-4a2c-9745-68363c56418a/download/malawi-tb-program-report-2014.pdf", |
| "url_type": "upload" | | "url_type": "upload" |
| } | | } |
| ], | | ], |
| "state": "active", | | "state": "active", |
| "tags": [ | | "tags": [ |
| { | | { |
| "display_name": "Report", | | "display_name": "Report", |
| "id": "37e5a5df-a993-4d3f-8c9c-73c418c30f0f", | | "id": "37e5a5df-a993-4d3f-8c9c-73c418c30f0f", |
| "name": "Report", | | "name": "Report", |
| "state": "active", | | "state": "active", |
| "vocabulary_id": null | | "vocabulary_id": null |
| } | | } |
| ], | | ], |
| "title": "Malawi TB Program Report 2014", | | "title": "Malawi TB Program Report 2014", |
| "type": "dataset", | | "type": "dataset", |
| "url": null, | | "url": null, |
| "version": null, | | "version": null, |
| "year": "2014" | | "year": "2014" |
| } | | } |